Aug 7, 2025 7:30 am EDT Achieve Life Sciences Reports Second Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program
Jul 29, 2025 8:30 am EDT Achieve Life Sciences to Participate in the BTIG Virtual Biotechnology Conference
Jul 24, 2025 8:30 am EDT Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 7, 2025
Jun 30, 2025 7:52 pm EDT Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriters’ Option to Purchase Additional Securities
Jun 26, 2025 11:43 pm EDT Achieve Life Sciences Announces Pricing of $45.0 Million Underwritten Public Offering
Jun 26, 2025 4:02 pm EDT Achieve Life Sciences Announces Partnership with Omnicom to Execute Integrated, Data-Driven Launch of the First Potential New Treatment for Nicotine Dependence in Nearly Two Decades
Jun 26, 2025 4:01 pm EDT Achieve Life Sciences Announces Submission of NDA to FDA for Cytisinicline as a Treatment of Nicotine Dependence for Smoking Cessation
May 28, 2025 8:30 am EDT Achieve Life Sciences to Present at the Jefferies Global Healthcare Conference
May 20, 2025 8:30 am EDT Achieve Life Sciences to Present New Data at the 2025 ATS International Conference Demonstrating that Cytisinicline Reduced Cravings and Nicotine Intake